Genomate Health Expands Global Footprint With Acquisition of Oncompass Medicine
Read MoreCombining trusted local expertise with global innovation to bring precision oncology to more patients.
Founded in Budapest in 2003, Oncompass Medicine has been a leader in personalized oncology for more than two decades. The company has supported patients and healthcare providers across Europe with advanced precision oncology services, developed some of the region’s first companion diagnostic tests, and became an early leader in implementing NGS-based tumor profiling.
This acquisition creates a unified European framework for Genomate Health, accelerating the company’s mission to make precision oncology accessible worldwide. By combining Oncompass Medicine’s operational excellence with Genomate Health’s computational reasoning technology, the company is building a fully integrated precision oncology platform that transforms complex molecular data into actionable treatment decisions at scale.
“Our priority is to ensure that precision oncology delivers its full potential for every patient. This acquisition allows us to close the gap between advanced molecular diagnostics and real-world patient access. It combines the advanced computational technology of Genomate with Oncompass Medicine’s clinical expertise to deliver the best cancer care worldwide.”
“We are not just expanding our geographic footprint, we are uniting two complementary strengths to redefine how cancer care is delivered. This strategic step positions us to lead the global transformation of oncology through data-driven precision medicine.”
Genomate Health, a precision oncology company headquartered in Cambridge, Massachusetts, has acquired Oncompass Medicine, the Hungarian leader in personalized oncology. The acquisition unites the two organizations under one global structure, bringing U.S. investment, international reach, and clinical market access to the European market.
Genomate Health is expanding rapidly in the United States and globally. By combining Oncompass Medicine’s operational excellence with Genomate Health’s computational reasoning technology, the company is building a fully integrated precision oncology platform that transforms complex molecular data into actionable treatment decisions at scale.
The acquisition gives Hungarian patients access to the world’s most advanced computational oncology technology, developed and clinically validated in the U.S. It also ensures continued access to trusted local diagnostics, now supported by expanded resources, global data, and AI-powered reasoning capabilities.
We’re expanding our capabilities, scaling access, and working on new solutions to make precision oncology faster, more accessible, and more effective for patients worldwide.
For more information about this acquisition or any Genomate Health related updates, please reach out to our Head of Marketing & Brand: Alina Luchian - alina.luchian(at)genomate.health.
.avif)
